Centro Gutman
Centro Gutman, ubicado en Palermo (CABA, Argentina), se especializa en oncología. Con 4 años de trayectoria, realiza estudios clínicos Fase II-IV. Cuenta con laboratorio, hospital de día y un equipo multidisciplinario. Enfocado en la atención diaria del paciente, impulsa investigación clínica de calidad con recursos innovadores y colaboración multi sponsor.Av. Sta. Fe 3233, C1425BGH Cdad. Autónoma de Buenos Aires, Argentina
Websitehttps://icm.center
Select an option
I am a doctor
I am a sponsor
Patients Benefits
Sistema de traslado centralizado
Sistema de reembolso a participantes sin latencia
Hotelería en proximidad para pacientes del interior
Our team
Medical staff
Marcela De Souza
Mariano Dioca
Nicolás Torressi
Fernando Galanternik
Open studies
Lung cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZenecaSee more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZenecaSee more
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) - TACTI-004 - Merck Sharp & Dohme LLCSee more
Fatty liver/nash
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.See more
Steatohepatitis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.See more
Bladder Cancer
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer - MoonRISe-1 - Janssen Research & Development, LLCSee more
Breast Cancer
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - TROPION-Breast05 - AstraZenecaSee more
Carcinoid Syndrome
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Carcinoid tumor
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
Colorectal cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - AmgenSee more
Gastrointestinal Cancer
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Liver cancer
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Pancreatic cancer
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Urothelial cancer
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.See more
